Lyme Disease Vaccination: Are We Ready To Try Again?

The Lancet Infectious Diseases

Volumn 13, Issue 8, 2013, Pages 643-644

  Lantos, Paul M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LYME DISEASE VACCINE; OUTER SURFACE PROTEIN A;

DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; HERD IMMUNITY; HUMAN; LETTER; LYME DISEASE; MASS IMMUNIZATION; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; FEMALE; HUMANS; LIPOPROTEINS; LYME DISEASE VACCINES; MALE;

EID: 84880701887     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70085-9     Document Type: Letter

References (16)

1. Barbour AG, Tessier SL, Todd WJ Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect Immun 1983, 41:795-804.
2. Simon MM, Schaible UE, Kramer MD, et al. Recombinant outer surface protein A from Borrelia burgdorferi induces protective antibodies against spirochetal infection in mice. J Infect Dis 1991, 164:123-132.
3. Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998, 339:216-222.
4. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998, 339:209-215.
5. Shadick NA, Liang MH, Phillips CB, Fossel K, Kuntz KM The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med 2001, 161:554-561.
6. Hsia EC, Chung JB, Schwartz JS, Albert DA Cost-effectiveness analysis of the Lyme disease vaccine. Arthritis Rheum 2002, 46:1651-1660.
7. Meltzer MI, Dennis DT, Orloski KA The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 1999, 5:321-328.
8. Wressnigg N, Pöllabauer E-M, Aichinger G, et al. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis 2013, published online May 10. http://dx.doi.org/10.1016/S1473-3099(13)70110-5.
9. Reported cases of Lyme disease-United States, 2011 Centers for Disease Control and Prevention, Sept 12, (accessed May 7, 2013). http://www.cdc.gov/lyme/stats/maps/map2011.html.
10. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43:1089-1134.
11. Aronowitz RA The rise and fall of the lyme disease vaccines: a cautionary tale for risk interventions in American medicine and public health. Milbank Q 2012, 90:250-277.
12. Poland GA Vaccines against Lyme disease: what happened and what lessons can we learn?. Clin Infect Dis 2011, 52(suppl 3):s253-s258.
13. Süss J Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview. Ticks Tick Borne Dis 2011, 2:2-15.
14. Heinz FX, Holzmann H, Essl A, Kundi M Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 2007, 25:7559-7567.
15. Kunze U, Isw TBE Conference report of the 10th meeting of the international scientific working group on tick-borne encephalitis (ISW-TBE): combating tick-borne encephalitis: vaccination rates on the rise. Vaccine 2008, 26:6738-6740.
16. Kosnik IG, Lah AK A campaign to increase the vaccination rate in a highly endemic tick-borne encephalitis region of Slovenia. Vaccine 2013, 31:732-734.